glp-1 agonist America's Poison Centers GLP-1 Receptor Agonists Explained for
Description
Santacruzamate A, HDAC2 inhibitor, 1 nM
Most incretin-based compounds target only the first two the addition of glucagon receptor agonism distinguishes this compound in research settings
In NAFLD patients, it is quite active
They were interested in whether there were subgroups of patients that may be at risk, with the goal of identifying them so that clinicians could have a better idea of who they should monitor more closely
This review highlights key clinical considerations across reproductive stages, emphasizes the primacy of human exposure data where available, and identifies critical evidence gaps requiring future prospective study
Seong JM, Yee J, Gwak HS
